查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1560942

2024-2032 年按成分、目标、应用、最终用户和地区分類的抗体药物偶联物市场报告

Antibody Drug Conjugates Market Report by Component, Target, Application, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 141 Pages | 商品交期: 2-3个工作天内

价格

2023年，全球抗体药物偶联物市场规模达78IMARC Group美元。

抗体药物偶联物 (ADC) 是包含肿瘤靶向抗体的高效生物药物，这些抗体透过化学方式附着在细胞毒性效应分子上。它们透过可生物降解的连接体将细胞毒性抗癌剂连接到单株抗体(mAb)，并允许健康组织和患病组织之间的敏感分叉，从而将细胞毒性抗癌剂传递给受影响的细胞。与标准化疗生物活性化合物相比，它们有助于提高 mAb 的细胞杀伤潜力、增强药物耐受性并限制系统暴露。目前，它们透过静脉注射进入血流，以避免单株抗体被胃酸和蛋白质水解酶降解。

抗体药物偶联物市场趋势：

由于久坐的生活方式以及经常吸烟和饮酒的人数不断增加，世界各地癌症的盛行率增加。这与对具有成本效益和成功的癌症治疗的需求不断增长相结合，是推动市场成长的关键因素之一。除此之外，现有的连接器经常非特异性地释放有效负载并导致脱靶毒性，这严重影响了ADC的开发。因此，领先企业不断资助他们的研发 (R&D) 项目，以优化现有的化学触发器并开发新型化学触发剂以产生高度选择性的连接体。他们还提出了新颖的接头-抗体配件，以生产稳定且同质的 ADC，以及额外的接头-有效负载附件，以允许扩展有效负载。此外，他们还致力于改善吸收、分布、代谢和排泄，这创造了良好的市场前景。其他主要因素，包括显着改善医疗基础设施、提高对癌症治疗方法的认识以及引入可裂解连接器技术，预计将推动市场成长。

本报告回答的关键问题：

  • 迄今为止，全球抗体药物偶联物市场表现如何，未来几年将如何表现？
  • COVID-19 对全球抗体药物偶联物市场有何影响？
  • 主要区域市场有哪些？
  • 基于组件的市场区隔是什么？
  • 基于目标的市场区隔是什么？
  • 基于应用程式的市场区隔是什么？
  • 基于最终用户的市场区隔是什么？
  • 产业价值链的各个阶段是什么？
  • 该行业的关键驱动因素和挑战是什么？
  • 全球抗体药物偶联物市场的结构如何？
  • 产业竞争程度如何？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球抗体药物偶联物市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：按组成部分

  • 单株抗体
    • 市场趋势
    • 市场预测
  • 连结器
    • 市场趋势
    • 市场预测
  • 细胞毒剂
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：按目标

  • 抗体-蛋白质毒素缀合物
    • 市场趋势
    • 市场预测
  • 抗体螯合放射性核种缀合物
    • 市场趋势
    • 市场预测
  • 抗体-小分子药物偶联物
    • 市场趋势
    • 市场预测
  • 抗体-酵素结合物
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：按应用

  • 淋巴瘤
    • 市场趋势
    • 市场预测
  • 卵巢癌
    • 市场趋势
    • 市场预测
  • 肺癌
    • 市场趋势
    • 市场预测
  • 乳癌
    • 市场趋势
    • 市场预测
  • 脑肿瘤
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：按最终用户

  • 医院
    • 市场趋势
    • 市场预测
  • 专门癌症中心
    • 市场趋势
    • 市场预测
  • 学术研究机构
    • 市场趋势
    • 市场预测
  • 生技公司
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 10 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 11 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 12 章：价值链分析

第 13 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 14 章：价格分析

第15章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • ADC Therapeutics SA
    • Astellas Pharma Inc.
    • AstraZeneca plc
    • Celldex Therapeutics Inc.
    • F. Hoffmann-La Roche AG
    • Gilead Sciences Inc.
    • GlaxoSmithKline Plc
    • ImmunoGen Inc
    • Pfizer Inc.
    • Sanofi SA
    • Seagen Inc.
    • Sorrento Therapeutics Inc.
    • Takeda Pharmaceutical Company Ltd.
Product Code: SR112024A4604

The global antibody drug conjugates market size reached US$ 7.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 43.7 Billion by 2032, exhibiting a growth rate (CAGR) of 20.5% during 2024-2032.

Antibody drug conjugates (ADCs) are highly potent biological drugs comprising tumor-targeting antibodies, which are chemically attached to a cytotoxic effector molecule. They deliver cytotoxic anticancer agents to affected cells by connecting them to monoclonal antibodies (mAb) through biodegradable linkers and allowing sensitive bifurcation between healthy and diseased tissues. They assist in increasing the cell-killing potential of mAb, enhancing drug tolerability, and limiting systematic exposure compared to standard chemotherapy bioactive compounds. At present, they are administered intravenously into the bloodstream to avoid gastric acid and proteolytic enzyme degradation of the mAb.

Antibody Drug Conjugates Market Trends:

Due to sedentary lifestyles and the rising number of individuals who smoke and drink regularly, there is an increase in the prevalence of cancer around the world. This, in confluence with the escalating demand for cost-effective and successful cancer treatments, represents one of the key factors bolstering the growth of the market. Apart from this, the existing linkers often release payloads nonspecifically and lead to off-target toxicity, which severely affects the development of ADCs. As a result, leading players are continuously funding their research and development (R&D) projects to optimize the existing chemical triggers and develop novel chemical triggers to generate highly selective linkers. They are also coming up with novel linker-antibody attachments to produce stable and homogenous ADCs and additional linker-payload attachments to allow the expansion of payloads. Moreover, they are focusing on improving the absorption, distribution, metabolism, and excretion, which is creating a favorable market outlook. Other major factors, including considerably improving healthcare infrastructure, increasing awareness about therapies available for cancer treatments, and the introduction of cleavable linker technology, are anticipated to propel the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global antibody drug conjugates market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on component, target, application and end user.

Breakup by Component:

  • Monoclonal Antibodies
  • Linker
  • Cytotoxic Agent
  • Others

Breakup by Target:

  • Antibody-Protein Toxin Conjugates
  • Antibody-Chelated Radionuclide Conjugates
  • Antibody-Small-Molecule Drug Conjugates
  • Antibody-Enzyme Conjugates

Breakup by Application:

  • Lymphoma
  • Ovarian Cancer
  • Lung Cancer
  • Breast Cancer
  • Brain Tumor
  • Others

Breakup by End User:

  • Hospitals
  • Specialized Cancer Centers
  • Academic Research Institutes
  • Biotechnology Companies
  • Others

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being ADC Therapeutics SA, Astellas Pharma Inc., AstraZeneca plc, Celldex Therapeutics Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline Plc, ImmunoGen Inc, Pfizer Inc., Sanofi S.A., Seagen Inc., Sorrento Therapeutics Inc. and Takeda Pharmaceutical Company Ltd.

Key Questions Answered in This Report:

  • How has the global antibody drug conjugates market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global antibody drug conjugates market?
  • What are the key regional markets?
  • What is the breakup of the market based on the component?
  • What is the breakup of the market based on the target?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global antibody drug conjugates market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Antibody Drug Conjugates Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Component

  • 6.1 Monoclonal Antibodies
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Linker
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Cytotoxic Agent
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Target

  • 7.1 Antibody-Protein Toxin Conjugates
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Antibody-Chelated Radionuclide Conjugates
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Antibody-Small-Molecule Drug Conjugates
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Antibody-Enzyme Conjugates
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Lymphoma
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ovarian Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Lung Cancer
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Breast Cancer
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Brain Tumor
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Specialized Cancer Centers
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Academic Research Institutes
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Biotechnology Companies
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 ADC Therapeutics SA
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
    • 15.3.2 Astellas Pharma Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 AstraZeneca plc
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Celldex Therapeutics Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 F. Hoffmann-La Roche AG
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 Gilead Sciences Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 GlaxoSmithKline Plc
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 ImmunoGen Inc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Pfizer Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Sanofi S.A.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Seagen Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Sorrento Therapeutics Inc.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
    • 15.3.13 Takeda Pharmaceutical Company Ltd.
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Antibody Drug Conjugates Market: Major Drivers and Challenges
  • Figure 2: Global: Antibody Drug Conjugates Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Antibody Drug Conjugates Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Antibody Drug Conjugates Market: Breakup by Component (in %), 2023
  • Figure 5: Global: Antibody Drug Conjugates Market: Breakup by Target (in %), 2023
  • Figure 6: Global: Antibody Drug Conjugates Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Antibody Drug Conjugates Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Antibody Drug Conjugates Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Antibody Drug Conjugates (Monoclonal Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Antibody Drug Conjugates (Monoclonal Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Antibody Drug Conjugates (Linker) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Antibody Drug Conjugates (Linker) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Antibody Drug Conjugates (Cytotoxic Agent) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Antibody Drug Conjugates (Cytotoxic Agent) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Antibody Drug Conjugates (Other Components) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Antibody Drug Conjugates (Other Components) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Antibody Drug Conjugates (Antibody-Protein Toxin Conjugates) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Antibody Drug Conjugates (Antibody-Protein Toxin Conjugates) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Antibody Drug Conjugates (Antibody-Chelated Radionuclide Conjugates) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Antibody Drug Conjugates (Antibody-Chelated Radionuclide Conjugates) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Antibody Drug Conjugates (Antibody-Small-Molecule Drug Conjugates) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Antibody Drug Conjugates (Antibody-Small-Molecule Drug Conjugates) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Antibody Drug Conjugates (Antibody-Enzyme Conjugates) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Antibody Drug Conjugates (Antibody-Enzyme Conjugates) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Antibody Drug Conjugates (Lymphoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Antibody Drug Conjugates (Lymphoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Antibody Drug Conjugates (Ovarian Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Antibody Drug Conjugates (Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Antibody Drug Conjugates (Lung Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Antibody Drug Conjugates (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Antibody Drug Conjugates (Breast Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Antibody Drug Conjugates (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Antibody Drug Conjugates (Brain Tumor) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Antibody Drug Conjugates (Brain Tumor) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Antibody Drug Conjugates (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Antibody Drug Conjugates (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Antibody Drug Conjugates (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Antibody Drug Conjugates (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Global: Antibody Drug Conjugates (Specialized Cancer Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Global: Antibody Drug Conjugates (Specialized Cancer Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Global: Antibody Drug Conjugates (Academic Research Institutes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Global: Antibody Drug Conjugates (Academic Research Institutes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Global: Antibody Drug Conjugates (Biotechnology Companies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Global: Antibody Drug Conjugates (Biotechnology Companies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Global: Antibody Drug Conjugates (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Global: Antibody Drug Conjugates (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: North America: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: North America: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: United States: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: United States: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Canada: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Canada: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Asia-Pacific: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Asia-Pacific: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: China: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: China: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Japan: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Japan: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: India: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: India: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: South Korea: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: South Korea: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Australia: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Australia: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Indonesia: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Indonesia: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Others: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Others: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Europe: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Europe: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Germany: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Germany: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: France: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: France: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: United Kingdom: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: United Kingdom: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Italy: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Italy: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Spain: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Spain: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Russia: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Russia: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Others: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Others: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Latin America: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Latin America: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Brazil: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 88: Brazil: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 89: Mexico: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 90: Mexico: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 91: Others: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 92: Others: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 93: Middle East and Africa: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 94: Middle East and Africa: Antibody Drug Conjugates Market: Breakup by Country (in %), 2023
  • Figure 95: Middle East and Africa: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 96: Global: Antibody Drug Conjugates Industry: SWOT Analysis
  • Figure 97: Global: Antibody Drug Conjugates Industry: Value Chain Analysis
  • Figure 98: Global: Antibody Drug Conjugates Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antibody Drug Conjugates Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Antibody Drug Conjugates Market Forecast: Breakup by Component (in Million US$), 2024-2032
  • Table 3: Global: Antibody Drug Conjugates Market Forecast: Breakup by Target (in Million US$), 2024-2032
  • Table 4: Global: Antibody Drug Conjugates Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Antibody Drug Conjugates Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Antibody Drug Conjugates Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Antibody Drug Conjugates Market: Competitive Structure
  • Table 8: Global: Antibody Drug Conjugates Market: Key Players